Should Autoimmune Encephalitis Antibody Tests Be Repeated?

If your initial commercial antibody panel comes back negative, you do not automatically need to repeat the test. A negative test lowers the chance that you have the specific antibodies included in that panel, but it does not completely rule out autoimmune encephalitis (AE). If your medical team still strongly suspects AE, the first step is to have an expert review your original test details. They may then decide to send samples to a specialized reference laboratory or repeat the test under specific conditions ^[1].

Important: Never delay emergency evaluation, and do not stop or postpone prescribed immune treatments solely to obtain another antibody test. If you are experiencing rapidly worsening confusion, new seizures, severe agitation, or altered consciousness, seek urgent medical care.

Evaluating Your First Test

Before ordering new tests, a specialist (like a neuroimmunologist) will audit your initial negative panel to see if anything was missed:

• Were both blood (serum) and spinal fluid (CSF) tested? Testing only blood is a common reason relevant antibodies are missed. Depending on the specific antibody, some are more easily detected in blood, while others are more reliably found in CSF. In one study of an AE patient group, 36% had antibodies only in their blood, while 9% had them only in their CSF, which is why paired testing of both fluids is generally recommended ^[2][3].
• Did treatment complicate the results? Immune therapies can affect test accuracy. Plasma exchange (PLEX) can physically remove antibodies from your blood, while intravenous immunoglobulin (IVIG) can introduce donor antibodies that make your test harder to interpret ^[4]. While samples are ideally drawn before treatment begins, urgent treatment for suspected AE should never be delayed just to wait for testing ^[5].
• What did the panel cover? Standard commercial panels look for the most common, well-known antibodies. If your symptoms point to a rarer subtype, the standard kit may not have included that specific target.

Commercial vs. Reference Laboratories

Standard commercial kits usually rely on fixed cell-based assays (CBAs). A CBA is a highly specific test designed to look for a known antibody. While commercial CBAs are very useful, they can sometimes miss antibodies (false negatives) depending on the exact kit and target ^[6].

If your clinical picture still strongly suggests AE, your doctor may consult a reference laboratory (such as a specialized university or specialized clinic lab). These labs can offer complementary testing methods, though no test is perfect:

• Tissue-based assays (TBAs): Instead of looking for a specific target, TBAs apply your fluid sample to thin slices of animal brain tissue to see if your immune system reacts to the tissue broadly. This acts as a screening tool ^[7]. However, a reaction on a TBA can sometimes be non-specific. If it detects an “unnamed” antibody, this is considered investigational and does not automatically prove you have a specific disease; it requires careful clinical correlation ^[8].
• Advanced Cell-based assays (CBAs): Reference labs may use highly sensitive in-house CBAs to confirm exactly which specific antibody is present if the TBA screening shows a reaction ^[7].
• Live-neuron testing: In highly complex cases, specialized centers may use live brain cells (rather than fixed/preserved cells) to see if antibodies bind to them. This is a highly specialized tool, not universally available, used to resolve confusing results ^[1].

The Risks of Repeating Tests Indiscriminately

Indiscriminate testing—meaning repeating the exact same standard commercial panels over and over without a clear clinical reason—can actually complicate your care.

• Low yield: Routinely repeating the same broad panel when your situation hasn’t changed is rarely helpful. In one retrospective study of patients undergoing repeat testing, the results changed the patient’s medical management in less than 1% of cases ^[9].
• False positives and misdiagnosis: Every time you run a broad medical test, there is a risk of a false positive. Sometimes, tests will flag a “weak positive” in the blood. While some low-level blood antibodies are clinically meaningful, isolated or weak serum reactivity requires expert interpretation. Overinterpreting weak, non-specific blood results without matching symptoms is a known contributor to misdiagnosis, which can lead to inappropriate and heavy immune-suppressing treatments ^[10][11].

When Is Repeat or Specialized Testing Useful?

Rather than automatically repeating a negative panel, your specialist may recommend targeted retesting or reference lab review if:

• Only one fluid (e.g., only blood) was initially tested.
• The original panel did not include the specific antibody suspected for your symptoms.
• Your initial samples were drawn after you received treatments like IVIG or PLEX.
• Your symptoms significantly evolve, or you experience a severe relapse ^[12].
• There is a new concern for a paraneoplastic syndrome (an immune reaction triggered by an underlying cancer).
• A newly validated test becomes available for a recently discovered antibody.

Understanding “Seronegative” Autoimmune Encephalitis

If your tests remain negative, it does not mean you definitely do not have AE. You may be diagnosed with seronegative autoimmune encephalitis (antibody-negative AE).

This is a clinical diagnosis of exclusion ^[1]. It is not diagnosed simply by having symptoms and a negative test. Instead, specialists will carefully confirm that your symptoms match AE, look for supportive clues (like specific changes on an MRI, EEG, or inflammation in your CSF), and rigorously rule out mimics—such as hidden infections, metabolic issues, psychiatric conditions, or tumors. If you meet these strict criteria, your team will personalize a treatment plan for you, even without a positive antibody test.